HGEN

Humanigen Inc.

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$91.4M

Burn Rate (Qtr)

$30.8M

Company Profile

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody. Lenzilumab is a monoclonal antibody that has been proven in animal models to neutralize GM-CSF.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Lenzilumab

COVID-19

Phase 3 (EUA / BLA filing / approval / launch)

Q4 2020

Lenzilumab

Prevention / treatment of Hyper-inflammation / Cytokine Storm

Phase 3 Topline Data

1Q'21

Lenzilumab

Prevention/Treatment of Acute GvHD

Phase 2/3 Initiation

TBD

Lenzilumab

Eosinophilic Asthma (EA)

Phase 3 Initiation

TBD

Lenzilumab

Efficacy/Toxicity Linkage
Prophylaxis as sequenced therapy with Yescarta (CAR-T) in r/r DLBCL

Phase 1b/2 data

TBD

Lenzilumab

Relapsed or Refractory Diffuse Large B-Cell Lymphoma / RR DLBCL

Phase 1b (Results)

Q4 2020

Ifabotuzumab | KB004

Glioblastoma Multiforme (GBM)

Phase 1

H1 2021

Recent Posts

See what the community is saying - click to see full post

HGEN - Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to De

HGEN - Humanigen Announces Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19

HGEN - Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal

HGEN - Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal

Are IL-6 Inhibitors still alive as a Covid Treatment?

Do failures of IL-6 blockers read thru to HGEN's Lenzilumab?

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon